ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1350	National Cancer Institute	Html	en	Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult central nervous system tumors.	treatment 0.515559 malignant tumor cells 0.227722 general information 0.262069 NCI-supported cancer 0.222651 cancer cells 0.27674 type 0.244277 spinal cord tumors 0.473603 clinical trial search 0.391071 brain tumors 0.2801 spinal cord 0.914442 tumor cells 0.493038 normal cells 0.296092	clinical trial 0.432056 clinical trials 0.701078 brain tumor 0.235359 brain 0.738045 PDQ summary 0.285532 tumors 0.535252 cancer clinical trials 0.361596 tumor 0.77091 radiation therapy 0.479169 grade 0.218633 cancer 0.578346 information 0.296506	CLICK HERE
1385	National Cancer Institute	Html	en	Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing ovarian, fallopian tube, and primary peritoneal cancers and about research aimed at the prevention of them.	oral contraceptives 0.660699 untreated subfertile women 0.554695 population-based case-control study 0.569591 multiple case-control studies 0.577558 tubal ligation 0.612813 ovarian cancer subtypes 0.638647 endometrioid carcinomas 0.557685 Ovarian Cancer Association 0.647707 invasive ovarian tumors 0.625952 tubal intraepithelial carcinoma 0.613375 case-control studies 0.724549 modest increased risk 0.571056 ovarian cancer 0.933826 clear cell carcinomas 0.577194 oral contraceptive therapy 0.556361 ovarian carcinoma 0.65109 ovarian reserve 0.599754 ovarian borderline tumor 0.646023 low-grade ovarian carcinomas. 0.649208 ovarian primary tumors. 0.639278 high-grade carcinomas 0.568553 cohort studies 0.697042 hospital-based case-control studies 0.582441 ovarian cancer cases 0.640486	epithelial ovarian cancers 0.62928 women 0.680224 borderline ovarian tumors 0.627194 prospective cohort studies 0.573074 risk reduction 0.631051 cohort study 0.558817 ovarian carcinomas 0.707015 clear cell cancer 0.56063 ovarian cancers 0.642329 unexposed infertile women 0.555673 observed risk reduction 0.618238 ovarian hyperstimulation 0.617463 significant increased risk 0.567639 high-grade serous carcinomas 0.73533 fallopian tube 0.554218 epithelial ovarian cancer 0.644523 ovarian cancer risk 0.740549 epidemiological studies 0.565 population-based case-control studies 0.621559 gastrointestinal primary tumors 0.557125 Netherlands cohort study 0.55691 ovarian carcinoma subtypes 0.642907 meta-analysis 0.563338 systematic review 0.583056	CLICK HERE
1754	National Cancer Institute	Html	en	Breast Reconstruction After Mastectomy	A fact sheet that describes breast reconstruction after mastectomy, including surgical options, follow-up care, and breast cancer screening after reconstruction.	breast reduction surgery 0.28849 tissue breast reconstruction 0.452019 flap reconstruction 0.330223 immediate reconstruction 0.31662 tissue 0.60196 breast reconstruction surgery 0.457163 mastectomy 0.359177 implant 0.307847 implant reconstruction 0.254395 breast numbness 0.249047 donor tissue 0.258639 breast skin 0.288491 early-stage breast cancer 0.279638 natural breast shape 0.273514 pedicled flap reconstruction 0.298564 autologous tissue reconstruction 0.366797 breast cancer experience 0.279508 reconstructed breast 0.419512 autologous reconstruction 0.246473 tissue expander 0.25279 blood vessels 0.426971 chest wall tissue 0.239092 entire breast 0.302278 Delayed reconstruction 0.247408 breast cancer therapy 0.323533	radiation therapy 0.283075 breast reconstruction technique 0.360333 breast forms 0.256638 external breast prostheses 0.334034 women 0.280496 surgical nipple reconstruction 0.280177 breast reconstruction method 0.374498 breast reconstruction 0.909174 breast rebuilt 0.281588 free flap reconstruction 0.325097 breast cancer recurrence 0.30156 woman considering breast 0.279422 breast tissue 0.318522 flap 0.344123 sufficient breast volume 0.289888 autologous tissue 0.583784 Breast Implants page 0.303495 breast surgeons 0.246995 breast area 0.280597 breast cancer 0.510147 skin-sparing mastectomy 0.235094 Breast Disease 0.251106 inflammatory breast cancer 0.289892 chest tissue 0.237416	CLICK HERE
1786	National Cancer Institute	Html	es	Linfedema (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfedema.	siguientes áreas 0.436931 causa hinchazón 0.778344 pequeña cantidad 0.464081 pequeños cortes 0.452311 siguientes abordajes 0.459419 PDQ Linfedema 0.618416 sección información 0.436578 largo plazo 0.580542 protector solar 0.453778 sección manejo 0.432902 National Cancer Institute 0.432858 ropa flojos 0.450402 siguientes riesgos 0.424859	Instituto Nacional 0.463187 siguientes problemas 0.490486 linfedema atrapa 0.967072 Physician Data Query 0.535003 Estados Unidos 0.442188 estadio iii 0.728645 siguientes medidas 0.469803 linfa circula 0.531655 linfedema.ampliar anatomía 0.480452 siguientes pruebas 0.475048 uñas ayuda 0.454713 baja potencia 0.433231	CLICK HERE
1840	National Cancer Institute	Html	es	Tratamiento de la enfermedad trofoblástica de la gestación (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la enfermedad trofoblástica de la gestación.	Obstet Gynecol 0.314049 calificación pronóstica 0.330592 Agarwal R 0.309981 gestational trophoblastic tumor 0.470216 gynecologic oncology 0.31949 gestational trophoblastic tumour 0.330225 Sin embargo 0.495025 largo plazo 0.308011 drug-resistant gestational trophoblastic 0.316646 trophoblastic tumor simulating 0.31025 gestational trophoblastic 0.969098 high-risk gestational trophoblastic 0.417868 site trophoblastic tumor 0.331006 Epithelioid trophoblastic tumor 0.331525 oncology group study 0.309029 retrospective observational study 0.310708 trophoblastic neoplasia with 0.311489 trophoblastic tumor 0.525373 newlands es 0.321142 gestational trophoblastic neoplasia 0.524164 Gynecol Oncol 0.321149 Database Syst Rev 0.308864 placental site trophoblastic 0.326491 chemorefractory gestational trophoblastic 0.316598 Reprod Med 0.395131	gynecologic oncology group 0.309183 Lancet Oncol 0.308542 Organización Mundial 0.310432 tumores trofoblásticos epitelioides 0.326002 Lurain JR 0.332449 metastatic gestational trophoblastic 0.30963 Holden L 0.308229 Cancer Staging Manual 0.311272 Féderation Internationale 0.320433 trophoblastic disease 0.450228 with gestational trophoblastic 0.311191 trophoblastic tumours 0.335737 Recurrent gestational trophoblastic 0.309132 Clin Oncol 0.324887 sistema nervioso central 0.319546 low-risk gestational trophoblastic 0.340233 Charing Cross 0.316962 Gynaecol Obstet 0.314146 persistent gestational trophoblastic 0.309878 Short D 0.308931 FIGO Committee 0.309443 Charing Cross Hospital 0.309844 Obstet Gynaecol 0.310271 AJCC Cancer Staging 0.31188	CLICK HERE
2023	National Cancer Institute	Html	es	Prevención del cáncer de seno (mama) (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	Risk Assessment Tool 0.639814 enfermedad benigna 0.724402 voluntarios sanos 0.550874 siguientes afecciones 0.583572 posibles daños 0.559702 vía oral 0.551992 largo plazo 0.555083 carcinoma lobulillar situ 0.643038 National Cancer Institute 0.566999 vitamina a 0.552574 siguientes riesgos 0.550628 Instituto Nacional 0.618668 protección ayuda 0.699167	Physician Data Query 0.746401 Estados Unidos 0.579171 suficiente ejercicio 0.906195 siguientes características 0.59401 prevención revisa 0.554009 PDQ Prevención 0.599371 Menor exposición 0.569365 siguientes formas 0.705774 pequeñas llamadas lobulillos 0.645602 Mayor edad 0.567138 genes brca1 0.883252 conductos.ampliar anatomía 0.589939 siguientes sumarios 0.661886	CLICK HERE
3424	National Cancer Institute	Html	es	Informes de patología	Hoja informativa que describe el tipo de información que puede aparecer en un informe de patología, el cual contiene los resultados de la examinación visual y microscópica del tejido extirpado durante una biopsia o cirugía.	página del nci 0.749066 cromosoma filadelfia 0.760969 ¿Cuánto tiempo 0.803391 leucemia mielógena 0.766464 tipo southern 0.748591	Detecta fragmentos 0.751768 simple vista 0.960274 Instituto Nacional 0.833257 cuello uterino 0.83163	CLICK HERE
15650	National Cancer Institute	Html	en	Step 2: Application Receipt & Assignment	Information on the assignment numbers the Center for Scientific Review (CSR) creates once an application is submitted and other submission policies.	Application Type 0.237536 100,228th application 0.228911 program director 0.554123 peer review process 0.902016 initial peer review 0.326681 Scientific Review 0.216004 new application 0.239088 specific application 0.226573 Resubmission Applications 0.206964 research grant applications 0.359218 his/her assigned application 0.489157 specific budgetary limits 0.31822 Program Announcements 0.201839	pre-announced Request 0.201939 appropriate application form 0.353459 new grant 0.218872 NIH peer review 0.369648 Incomplete applications 0.208003 NCI program director 0.428336 suffix code 0.378185 grant numbers 0.228139 application 0.702093 NIH Policy 0.353037 traditional research project 0.330544 central receipt point 0.406816	CLICK HERE
16822	National Cancer Institute	Html	es	Essiac y Flor Essence (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de Essiac o Flor Essence como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Centro Nacional 0.301601 New Hampshire Avenue 0.301144 Drug Administration 0.30071 Flor Essence 0.987323 NCI Best Case 0.302063 modelos animales 0.300855 Indiana University-Purdue University 0.301652 datos bibliográficos pubmed 0.301216 siguientes preguntas 0.300694 productos essiac 0.309556 modelo animal 0.300781 PDQ Essiac 0.318217 National Cancer Institute 0.301364 Royal Cancer Commission 0.301752 Olmo resbaladizo 0.301149 siguientes riesgos 0.300858 Instituto Nacional 0.309533 Salud Complementaria 0.302607	Visuals Online 0.300813 complementarias revisa 0.30115 Physician Data Query 0.304689 Sloan Kettering Cancer 0.301678 Estados Unidos 0.332086 siguientes estudios 0.301314 libre uso 0.301062 distintos resultados 0.300776 únicos efectos 0.301309 ratón p388 0.301025 página manejo 0.300756 ¿El tratamiento 0.301379 Nueva York 0.300871 ¿Los beneficios 0.30071 juntos cam 0.300681 Series Program 0.300695 medicina complementaria 0.332457	CLICK HERE
16830	National Cancer Institute	Html	en	Clinical Trial Sequencing Project	null	gene expression test 0.968523 vital genomic information 0.445867 non-metastatic RCC 0.377128 breast cancer response 0.478667 Large B Cell 0.384272 NCTN clinical trials 0.448807 ECOG-ACRIN E2805 trial 0.421922 DLBCL patients 0.352651 National Clinical Trials 0.46574 molecular basis 0.431838 advanced RCC 0.374566 clinical trials 0.533121 VEGF inhibitors 0.375945 clinical trial 0.642586 RCC development 0.370697 breast cancer patients 0.519364 comprehensive molecular analysis 0.404401 Genomic Data Commons 0.460933 Trial Assigning Individualized 0.463121 cancer types 0.360865 surgical removal 0.412464 chemotherapy best complements 0.471441 large B-cell lymphoma 0.45172 cancer recurrence 0.405985 low-risk patients 0.363667	clinically helpful tool 0.4004 rich molecular data 0.400698 Combination Chemotherapy 0.375651 cancer research community 0.644574 adult non-Hodgkin lymphoma 0.414301 Her2-negative breast cancer 0.645596 NCI-sponsored clinical trial 0.620071 common kidney cancer 0.437411 endothelial growth factor 0.403689 different chemotherapy regimens 0.474741 human epidermal growth 0.418539 anonymized clinical data 0.446701 genomic alterations 0.360205 CCG 0.375478 NCI-sponsored clinical trials 0.472546 pathway drives RCC 0.461359 breast cancer 0.780189 best individualized treatment 0.43596 Clinical Trial Sequencing 0.508554 tissue samples 0.518757 breast cancer treatments 0.478341 renal cell carcinoma 0.625007 New England Journal 0.405702 Diffuse Large 0.405055	CLICK HERE